Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Wells Pharma of Houston LLC violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects Wells Pharma of Houston LLC: Form 483 with 6 Citations (March 28, 2025)

At a glance: FDA inspected Wells Pharma of Houston LLC in Texas and issued a Form 483 listing 6 inspectional observations following an inspection that concluded 2025-03-28. FDA records classify Wells Pharma of Houston LLC as a outsourcing facility. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Wells Pharma of Houston LLC
FEI / inspection ID	3016710931
Inspection end date	March 28, 2025
Citation count	6

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — Procedures designed to prevent microbiological contamination of drug products purporting to be

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed. Specifically, A) On March 17, 2025, your aseptic phaimacv technicians were observed holding the filtered drug product filled in a sterile opened bag in a[(o) (4)position that blocked first pass air in the [(6) (4 )ISO 5 Laminar Air Flow Hood (LAFH) during the preparation of the following batches: i. Fentanyl (2 mcg/ml) with 0.2% Ropivacaine HCL in 0.9% Sodium Chloride 100ml Bag, Lot:[{Q) (:21-) !, BUD: 07 / 15 /2025; and, ii. Midazolam ( lm~l ml) in 0.9% sodium chloride 50ml bag lmg/ml, Lot: [(6) (4) , BUD: 07/ 15 /2025. Your aseptic pharmacy technicians were also observed removing drug product from the bag into a syringe used for the entire batching proces;~ in (o) (4 )1 orientation that blocked the critical ai·eas from receiving first pass air fl ow from the (o) (4 )ISO 5 LAFH. This practice was.

Observation 2 — EMPLOY EE(S) SIGNATURE DATE ISS UED SEE REVERSE Jazmine N Br own

EMPLOY EE(S) SIGNATURE DATE ISS UED SEE REVERSE Jazmine N Br own, Investigat or 3/28/2025 OF THIS PAGE PAGE3of12PAGES FORM FDA ~83 (09/08) PREVIOUS BOffiON OBSOLEJE INSPECTIONAL OB SERVATIO NS

Observation 3 — There is a failure to thoroughly review any unexplained discrepancy and the

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of i ts components to meet any of its specifications whether or not the batch has been ah-eady distributed. Specifically, A) Your finn failed to investigate and follow up on an adverse event, PC-HOU-2024-008, initiated for a patient complaint. Your finn failed to follow your adverse event procedures, SOP HOU QA-041, Pharmacovigilance Procedure for Adverse Events, effective date 12Nov21, to ensure patient complaints ai-e appropriately investigated, followed up on, and reported in a timely manner. B) Your fnm failed to adequately incubate enviromnental monitoring plates fo r 1h1 (<ff batches of dmg products. Deviation, DEV-HOU-2025-002, was initiated due to the failure of incubating environmental monitoring plates for the appropriate time and temperature per SOP HOU-QC- 014, Environmental Monitoring for ISO 5, ISO 7, and ISO 8 Classified Environments, effective date: 09Feb24. The environmental monitoring plates were not removed from the initial incubation.

Observation 4 — The responsibilities and procedures applicable to the quality control unit are not

The responsibilities and procedures applicable to the quality control unit are not in writing and fully fo llowed. Specifically, A) Your fum 's visual inspection process governed by SOP HOU-QC-006, Finished Sterile Product Visual Insp ection, effective date 03Jul24, is de fi cient in that: 1. Your fum 's procedure does not require Quality Assurance approval prior to initiating a second 100% visual inspection after an Acceptable Quality Limit (AQL) h as been per fo nned from the initial 100% failed visual inspection and fails to include ~(o) (4~ AQL after the second 100% visual inspection, if perfo1med. 2. Your fum 's visual inspection process fails to categorize de fe cts as critical, major, or minor with acceptance and rejection rates within the categories when visually inspecting bags, syringes, and vial units. 3. Your fum 's visual inspection process is de fi cient in that it does not require identification of paiticulates fo und dur ing the visual inspection process.

Observation 5 — Equipment used in the manufacture, processing, packing or holding of diug products

Equipment used in the manufacture, processing, packing or holding of diug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance. Specifically, A) Your fum failed to perfo1m protocol di·iven equipment qualification shldies for the'.(6) (4Ji [ "I, used for steriliz ing goggles worn in the clean room. Steriliz ing cycles are not qualified for personal protection equipment, goggles worn in the cleanroom. Additionally, your fum failed to place the biological indicators in one of the [(6) (,4 )Jbeing sterilized when setting up anK 6) (m rnn as instrncted by your film's procedure, SOP HOU EQ-021, Use, Care, and Maintenance of the (b (4) , effective date 27Aug2 1. B) During the walkthrough perfo1med on 03/l 7/2025, cracked plexiglass siding with an appearance of a yellowish brown and black discoloration was obse1ved around the metal brackets used to hold th (6) (4) Ibar in place on !(6) -(4) plexiglass panels affecting 4 (b).

Observation 6 — The labels of your outsourcing facility's drng products do not include information

The labels of your outsourcing facility's drng products do not include information required by section 503B(a)(I0)(A) of the Federal Food, Drng, and Cosmetic Act (FD&C Act). Specifically, the following info1mation is not found on your diug product labels: a) The statement "This is a compounded diug"; Examples of your diug product labels that do not contain this info rmation, include but are not limited to: • Fentanyl 1000 mcg/100 mL (10 mcg per mL) Injectable Solution in 0.9% Sodium Chloride EMPLOY EE(S) SIGNATURE DAT E ISSUED SEE REVERSE Jazmine N Br own, Investigat o r 3/ 2 8/ 2025 OF THIS PAGE F ORM FDA ~83 (09/ 08) PREVIOUS BOffiON OBSOLEJE INSPECTIONAL OB SERVATIO NS PAGE 10 of 12 PAGES

Wells Pharma of Houston LLC’s FDA history

Argus HQ has recorded 9 total FDA actions tied to Wells Pharma of Houston LLC: 0 warning letters, 7 recalls, 0 approval records, and 2 Form 483 inspection citations.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Wells Pharma of Houston LLC violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Wells Pharma of Houston LLC

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Inspects Wells Pharma of Houston LLC: Form 483 with 6 Citations (March 28, 2025). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2025-03-28-3016710931

MLA

"FDA Inspects Wells Pharma of Houston LLC: Form 483 with 6 Citations (March 28, 2025)." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2025-03-28-3016710931.

Chicago

Argus HQ Research. "FDA Inspects Wells Pharma of Houston LLC: Form 483 with 6 Citations (March 28, 2025)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2025-03-28-3016710931.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_wells_pharma_of_houston_llc_2025_03_28_3016710931_2025,
  title = {FDA Inspects Wells Pharma of Houston LLC: Form 483 with 6 Citations (March 28, 2025)},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2025-03-28-3016710931},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗